Differential regulation of Wnt/beta-catenin signaling by Liver X Receptors in Schwann cells and oligodendrocytes.
暂无分享,去创建一个
[1] J. Gustafsson,et al. Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease , 2012, Proceedings of the National Academy of Sciences.
[2] Tomas Jakobsson,et al. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. , 2012, Trends in pharmacological sciences.
[3] M. Ameloot,et al. Liver X receptors regulate cholesterol homeostasis in oligodendrocytes , 2012, Journal of neuroscience research.
[4] V. Leoni,et al. Oxysterols as biomarkers in neurodegenerative diseases. , 2011, Chemistry and physics of lipids.
[5] W. Sierralta,et al. 27-hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype. , 2011, Oncology reports.
[6] M. Schumacher,et al. Interplay between LXR and Wnt/β-Catenin Signaling in the Negative Regulation of Peripheral Myelin Genes by Oxysterols , 2011, The Journal of Neuroscience.
[7] M. García-Villanueva,et al. A novel myelin protein zero (V136G) homozygous mutation causing late onset demyelinating polyneuropathy with brain white matter lesions , 2011, Clinical Neurology and Neurosurgery.
[8] M. Schumacher,et al. Wnt/β-Catenin Signaling Is an Essential and Direct Driver of Myelin Gene Expression and Myelinogenesis , 2011, The Journal of Neuroscience.
[9] A. Faden,et al. Modulation of ABCA1 by an LXR agonist reduces β-amyloid levels and improves outcome after traumatic brain injury. , 2011, Journal of neurotrauma.
[10] K. Davis,et al. Peripheral myelin protein-22 is expressed in CNS myelin , 2010, Translational neuroscience.
[11] R. Ostrowski,et al. Activation of liver X receptor reduces global ischemic brain injury by reduction of nuclear factor-κB , 2010, Neuroscience.
[12] E. Mazzon,et al. Liver X receptor agonist treatment regulates inflammatory response after spinal cord trauma , 2010, Journal of neurochemistry.
[13] M. Schumacher,et al. Cross-Talk between Oxysterols and Glucocorticoids: Differential Regulation of Secreted Phopholipase A2 and Impact on Oligodendrocyte Death , 2009, PloS one.
[14] Andrew J. Brown,et al. Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. , 2009, Molecular aspects of medicine.
[15] R. Moon,et al. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis , 2009, Cell Research.
[16] M. Schumacher,et al. 25‐hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR , 2009, Journal of neurochemistry.
[17] M. Makishima,et al. Suppression of beta-catenin signaling by liver X receptor ligands. , 2009, Biochemical pharmacology.
[18] B. Leber,et al. O-GlcNAc-glycosylation of beta-catenin regulates its nuclear localization and transcriptional activity. , 2008, Experimental cell research.
[19] Yimin Zou,et al. Wnt signaling in neural circuit assembly. , 2008, Annual review of neuroscience.
[20] P. Arlotta,et al. Conditional Knock-Out of β-Catenin in Postnatal-Born Dentate Gyrus Granule Neurons Results in Dendritic Malformation , 2007, The Journal of Neuroscience.
[21] D. Mangelsdorf,et al. Liver X receptors and cholesterol homoeostasis: spotlight on the adrenal gland. , 2006, Biochemical Society transactions.
[22] J. Cunningham,et al. Myelin protein zero mutation His39Pro: hereditary motor and sensory neuropathy with variable onset, hearing loss, restless legs and multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[23] M. Schumacher,et al. Differential recruitment of p160 coactivators by glucocorticoid receptor between Schwann cells and astrocytes. , 2006, Molecular endocrinology.
[24] M. Schumacher,et al. Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Mirsky,et al. The origin and development of glial cells in peripheral nerves , 2005, Nature Reviews Neuroscience.
[26] J. Gustafsson,et al. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] M. Schumacher,et al. Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.M400244-JLR200 , 2004, Journal of Lipid Research.
[28] R. Franklin,et al. The Mysteries of Myelin Unwrapped , 2004, Science.
[29] T. Sotnikova,et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] U. Suter,et al. Instructive Role of Wnt/ß-Catenin in Sensory Fate Specification in Neural Crest Stem Cells , 2004, Science.
[31] C. Polman,et al. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients , 2003, Neuroscience Letters.
[32] J. Hillert,et al. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis , 2002, Neuroscience Letters.
[33] J. Gustafsson,et al. Liver X receptors in the central nervous system: From lipid homeostasis to neuronal degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] P. Patel,et al. Identification of a positive regulatory element in the myelin‐specific promoter of the PMP22 gene , 2001, Journal of neuroscience research.
[35] D. Russell,et al. Oxysterol biosynthetic enzymes. , 2000, Biochimica et biophysica acta.
[36] F. Berenbaum,et al. Induction of Secreted Type IIA Phospholipase A2 Gene Transcription by Interleukin-1β , 2000, The Journal of Biological Chemistry.
[37] F. Jessen,et al. Plasma 24S‐hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease , 2000, Neuroreport.
[38] P. Patel,et al. Glucocorticosteroids stimulate the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells , 2000, Brain Research.
[39] M. Schumacher,et al. Validation of an analytical procedure to measure trace amounts of neurosteroids in brain tissue by gas chromatography-mass spectrometry. , 2000, Journal of chromatography. B, Biomedical sciences and applications.
[40] F. Jessen,et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. , 2000, Journal of lipid research.
[41] G. Lemke,et al. Multiple Regulatory Elements Control Transcription of the Peripheral Myelin Protein Zero Gene* , 1997, The Journal of Biological Chemistry.
[42] D. Mangelsdorf,et al. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. , 1997, Genes & development.
[43] D. Mangelsdorf,et al. An oxysterol signalling pathway mediated by the nuclear receptor LXRα , 1996, Nature.
[44] L. Shaffer,et al. Duplication of the PMP22 gene in 17p partial trisomy patients with Charcot-Marie-Tooth type-1A neuropathy , 1996, Human Genetics.
[45] M. Mersel,et al. Effect of Oxysterol Treatment on Cholesterol Biosynthesis and Reactive Astrocyte Proliferation in Injured Rat Brain Cortex , 1995, Journal of neurochemistry.
[46] Pierre Bougnères,et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[47] U. Suter,et al. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease , 2007, NeuroMolecular Medicine.
[48] F. Jessen,et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. , 2002, Journal of psychiatric research.
[49] J. Lupski,et al. Myelin protein zero (MPZ) gene mutations in nonduplication type 1 Charcot‐Marie‐Tooth disease , 1996, Human mutation.